Publications
Detailed Information
Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Therasa | - |
dc.contributor.author | Choi, He Yun | - |
dc.contributor.author | Lee, Hyun-Seo | - |
dc.contributor.author | Jung, Sung-Hoon | - |
dc.contributor.author | Ahn, Jae-Sook | - |
dc.contributor.author | Kim, Hyeoung-Joon | - |
dc.contributor.author | Lee, Je-Jung | - |
dc.contributor.author | Yoo, Hee-Doo | - |
dc.contributor.author | Yang, Deok-Hwan | - |
dc.date.accessioned | 2018-11-13T07:19:19Z | - |
dc.date.available | 2018-11-13T16:30:44Z | - |
dc.date.issued | 2018-07-09 | - |
dc.identifier.citation | BMC Cancer, 18(1):729 | ko_KR |
dc.identifier.issn | 1471-2407 | - |
dc.identifier.uri | https://hdl.handle.net/10371/143517 | - |
dc.description.abstract | Background
A relatively high proportion of patients diagnosed with primary CNS lymphoma will experience recurrent disease, yet therapy options are limited in salvage therapy. This is the first study to evaluate a bendamustine-based combination regimen for the treatment of relapsed/refractory PCNSL and to characterize bendamustine pharmacokinetics in the human CSF. Methods Patients received bendamustine 75mg/m2 for two days as part of R-B(O)AD administered intravenously every 4weeks for up to 4cycles. Response and adverse events of the regimen were assessed. A sparse sampling strategy and population based modeling approach was utilized for evaluation of plasma and CSF levels of bendamustine. Results Ten patients were enrolled into study of whom 70% were of refractory disease and with high IELSG prognostic risk scores. The ORR of R-BOAD was 50% (95% CI, 0.24 to 0.76) with one patient achieving CR and four PR. Primary toxicity of the regimen was reversible myelosuppression, mostly grade 3 or 4 neutropenia. The Cmax mean for plasma and CSF were 2669ng/mL and 0.397ng/mL, respectively, and patients with response at deep tumor sites displayed higher trends in peak exposure. Pharmacokinetic data was best described by a four-compartment model with first-order elimination of drug from central plasma and CSF compartments. Conclusions R-BOAD is an effective salvage option for PCNSL, but with significant hematologic toxicity. Bendamustine CSF levels are minimal; however correspond to plasma exposure and response. Trial registration ClinicalTrials.gov NCT03392714 ; retrospectively registered January 8, 2018. | ko_KR |
dc.description.sponsorship | This study was supported by a grant (HCRI 16915–1) provided from Chonnam National University Hwasun Hospital Institute for Biomedical Science. The funding body had no role in designing of the study, experimental analyses, or manuscript production | ko_KR |
dc.language.iso | en | ko_KR |
dc.subject | Bendamustine | ko_KR |
dc.subject | CSF | ko_KR |
dc.subject | Pharmacokinetics | ko_KR |
dc.subject | Primary CNS lymphoma | ko_KR |
dc.subject | Salvage therapy | ko_KR |
dc.title | Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL) | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 최혜윤 | - |
dc.contributor.AlternativeAuthor | 이현서 | - |
dc.contributor.AlternativeAuthor | 정성훈 | - |
dc.contributor.AlternativeAuthor | 안재숙 | - |
dc.contributor.AlternativeAuthor | 김형준 | - |
dc.contributor.AlternativeAuthor | 김제중 | - |
dc.contributor.AlternativeAuthor | 유희두 | - |
dc.contributor.AlternativeAuthor | 양덕환 | - |
dc.identifier.doi | 10.1186/s12885-018-4632-y | - |
dc.language.rfc3066 | en | - |
dc.rights.holder | The Author(s). | - |
dc.date.updated | 2018-07-15T03:29:08Z | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.